The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Favezelimab plus pembrolizumab in transplant-ineligible patients with R/R classical Hodgkin lymphoma
Nathalie Johnson, MD, PhD, Jewish General Hospital, Montreal, Canada, discusses the updated analysis of an open-label Phase I/II study (NCT03598608) investigating favezelimab in combination with pembrolizumab in transplant-ineligible patients with anti–PD-1–naïve relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). The study’s primary endpoint was safety, and the combination therapy was found to have a favorable safety profile. Common adverse events reported were manageable, such as hypothyroidism and infusion-related toxicities. The progression-free survival (PFS) data were promising compared to historical controls. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Gilead, Abbvie, Merck, Roche
Honoraria: Merck, Roche
